GLS and cancer: Small molecule GLS inhibitors such as bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES), CB-839, and compound 968, are able to inhibit GLS isoforms not commonly expressed in normal cells, allowing for greater selectivity in targeting cancer cells while reducing toxicity to normal cells [198,199].